Literature DB >> 22776191

Select agent and toxin regulations: beyond the eighth edition of the Guide for the Care and Use of Laboratory Animals.

Robin J Kastenmayer1, Rashida M Moore, Allison L Bright, Rafael Torres-Cruz, William R Elkins.   

Abstract

In the interval between the publication of the seventh and eighth editions of the Guide for the Care and Use of Laboratory Animals (Guide), much has changed with regard to the regulation and funding of highly pathogenic biologic agents and toxins (Select Agents). Funding of research involving highly pathogenic agents has increased dramatically during this time, thus increasing the demand for facilities capable of supporting this work. The eighth edition of the Guide briefly mentions Select Agents and provides a limited set of references. Here we provide some background information regarding the relevant laws and regulations, as well as an overview of the programmatic requirements pertaining to the use of Select Agents, with a focus on use in animals.

Mesh:

Substances:

Year:  2012        PMID: 22776191      PMCID: PMC3358982     

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.232


  9 in total

1.  Effects of the USA PATRIOT Act and the 2002 Bioterrorism Preparedness Act on select agent research in the United States.

Authors:  M Beatrice Dias; Leonardo Reyes-Gonzalez; Francisco M Veloso; Elizabeth A Casman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Federal agency biodefense funding, FY2010-FY2011.

Authors:  Crystal Franco; Tara Kirk Sell
Journal:  Biosecur Bioterror       Date:  2010-06

3.  Possession, use, and transfer of select agents and toxins. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2005-03-18

Review 4.  Select agent regulations.

Authors:  Janet C Gonder
Journal:  ILAR J       Date:  2005

Review 5.  Facility design considerations for select agent animal research.

Authors:  Dan Frasier; Jeff Talka
Journal:  ILAR J       Date:  2005

Review 6.  Administrative issues related to infectious disease research in the age of bioterrorism.

Authors:  Jerry Jaax
Journal:  ILAR J       Date:  2005

Review 7.  Clinical laboratories, the select agent program, and biological surety (biosurety).

Authors:  Ross H Pastel; Gretchen Demmin; Grant Severson; Rafael Torres-Cruz; Jorge Trevino; John Kelly; Jay Arrison; Joy Christman
Journal:  Clin Lab Med       Date:  2006-06       Impact factor: 1.935

8.  Habeas Corpus Petitions and the Antiterrorism and Effective Death Penalty Act of 1996.

Authors:  Matthew DeLiere; Richard Martinez
Journal:  J Am Acad Psychiatry Law       Date:  2016-12

9.  Possession, use, and transfer of select agents and toxins--reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments. Interim final rule.

Authors: 
Journal:  Fed Regist       Date:  2005-10-20
  9 in total
  12 in total

1.  USP47 stabilizes BACH1 to promote the Warburg effect and non-small cell lung cancer development via stimulating Hk2 and Gapdh transcription.

Authors:  Jing Peng; Wencan Li; Nianxi Tan; Xihua Lai; Weilin Jiang; Guang Chen
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

2.  Long non-coding RNA RPL34-AS1 ameliorates oxygen-glucose deprivation-induced neuronal injury via modulating miR-223-3p/IGF1R axis.

Authors:  Xin-Ya Wei; Tian-Qi Zhang; Rui Suo; You-Yang Qu; Yan Chen; Yu-Lan Zhu
Journal:  Hum Cell       Date:  2022-08-25       Impact factor: 4.374

3.  Challenges and Practices in Building and Implementing Biosafety and Biosecurity Programs to Enable Basic and Translational Research with Select Agents.

Authors:  Colleen B Jonsson; Kelly Stefano Cole; Chad J Roy; David S Perlin; Gerald Byrne
Journal:  J Bioterror Biodef       Date:  2013-04-29

4.  Evaluation of Gram-negative bacterial infection by a stable and conjugative bioluminescence plasmid in a mouse model.

Authors:  Yao-Kuang Huang; Chishih Chu; Chih-Hsiung Wu; Chyi-Liang Chen; Cheng-Hsun Chiu
Journal:  J Biomed Sci       Date:  2014-08-19       Impact factor: 8.410

5.  Effect of transplantation of olfactory ensheathing cell conditioned medium induced bone marrow stromal cells on rats with spinal cord injury.

Authors:  Linjie Feng; Hongquan Gan; Wenguo Zhao; Yingjie Liu
Journal:  Mol Med Rep       Date:  2017-06-20       Impact factor: 2.952

6.  MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.

Authors:  Shuzhen Tian; Lili Lou; Mengyuan Tian; Guangping Lu; Jianghua Tian; Xi Chen
Journal:  J Exp Clin Cancer Res       Date:  2020-07-25

7.  Protective effect of morin on myocardial ischemia‑reperfusion injury in rats.

Authors:  Shuang Liu; Nan Wu; Jiaxin Miao; Zijun Huang; Xuying Li; Pengyu Jia; Yuxuan Guo; Dalin Jia
Journal:  Int J Mol Med       Date:  2018-06-26       Impact factor: 4.101

8.  Long non‑coding RNA GAS5 regulates myocardial ischemia‑reperfusion injury through the PI3K/AKT apoptosis pathway by sponging miR‑532‑5p.

Authors:  Yang Han; Nan Wu; Fei Xia; Shuang Liu; Dalin Jia
Journal:  Int J Mol Med       Date:  2020-01-20       Impact factor: 4.101

9.  Kinesin Family Member C1 (KIFC1) Accelerates Proliferation and Invasion of Endometrial Cancer Cells Through Modulating the PI3K/AKT Signaling Pathway.

Authors:  Kening Zhou; Jian Zhao; Lifang Qi; Yingying He; Jingui Xu; Mimi Dai
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

10.  A Universal Next-Generation Sequencing Protocol To Generate Noninfectious Barcoded cDNA Libraries from High-Containment RNA Viruses.

Authors:  Lindsey A Moser; Lisbeth Ramirez-Carvajal; Vinita Puri; Steven J Pauszek; Krystal Matthews; Kari A Dilley; Clancy Mullan; Jennifer McGraw; Michael Khayat; Karen Beeri; Anthony Yee; Vivien Dugan; Mark T Heise; Matthew B Frieman; Luis L Rodriguez; Kristen A Bernard; David E Wentworth; Timothy B Stockwell; Reed S Shabman
Journal:  mSystems       Date:  2016-06-07       Impact factor: 6.496

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.